GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Talis Biomedical
Talis Biomedical is a molecular diagnostics company. Its stock price reflects its difficult post-IPO history, which was marked by challenges launching its diagnostic platform. The chart tells the story of the company's struggle to correct errors and realize the technology's potential.
Share prices of companies in the market segment - Diagnostic medical equipment
Talis Biomedical has developed a compact molecular diagnostic platform for rapid testing of infectious diseases at the point of care. We have classified it as "Diagnostic Medical Equipment." The graph below shows the dynamics in the rapid diagnostics sector.
Broad Market Index - GURU.Markets
Talis Biomedical is a company that has developed a platform for rapid molecular diagnostics of infectious diseases at the point of care. As an innovator, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Talis' performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
TLIS - Daily change in the company's share price Talis Biomedical
Talis Biomedical Corporation's daily share price fluctuations reflect the volatility of the molecular diagnostics sector. This metric measures the stock's sensitivity to news regarding the development and commercialization of its diagnostic platforms.
Daily change in the price of a set of shares in a market segment - Diagnostic medical equipment
Talis Biomedical developed a platform for rapid molecular diagnostics of infectious diseases. The company encountered commercialization challenges, typical for this sector. The chart below shows the volatility in the medical diagnostics industry, illustrating the high risks such companies face.
Daily change in the price of a broad market stock, index - GURU.Markets
Talis Biomedical is a company specializing in molecular diagnostics. Its shares react to news of its tests' acceptance by the medical community. This specific volatility, driven by medical innovation, feeds into the overall market movement.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Talis Biomedical
Talis Biomedical Corporation's year-over-year performance is a story of adaptation to the post-pandemic world. Its market cap change over the past 12 months reflects its struggle to commercialize its molecular diagnostics platform following the challenges of its COVID-19 test. Its valuation is a bet on finding its niche in this market.
Annual dynamics of market capitalization of the market segment - Diagnostic medical equipment
Talis, as a diagnostics company, is betting on medical innovation. Its performance relative to the sector will reveal how much investors believe in its ability to commercialize its molecular testing platform, which is key to its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Talis Biomedical, a diagnostics company, tells the story of its search for a new strategy after the pandemic. Its performance, compared to the market, reflects whether investors believe in its ability to create in-demand tests for other diseases after the failure of its COVID-19 test.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Talis Biomedical
Talis is a molecular diagnostics company. Its monthly performance reflects its struggle to commercialize its rapid testing platform. News about interactions with the FDA and development progress are key.
Monthly dynamics of market capitalization of the market segment - Diagnostic medical equipment
Talis Biomedical has developed a compact molecular diagnostic platform for rapid testing of infectious diseases directly at the point of care. The graph below shows the dynamics of the diagnostics sector, which experienced a boom during the pandemic and is now seeking new growth opportunities.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Talis Biomedical is developing a platform for rapid molecular diagnostics of infectious diseases. This is a competitive market. The company's shares are driven by news of regulatory approvals and the commercial success of its tests, rather than by overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Talis Biomedical
The weekly performance of Talis, a diagnostics company, reflects the challenges in the infectious disease testing market. Its stock price is responding to competition and the company's ability to commercialize its rapid diagnostic platform in a post-pandemic environment.
Weekly dynamics of market capitalization of the market segment - Diagnostic medical equipment
Talis Biomedical has developed a rapid molecular diagnostic platform. This chart compares its weekly performance with the sector and helps understand how it compares to other point-of-care diagnostic systems and the relevance of its technology in the wake of the COVID-19 pandemic.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Talis Biomedical is a company in the medical diagnostics sector. Shares of such companies may be less dependent on general economic cycles. This chart will help us understand whether Talis shares are stuck in a world of clinical trials and the introduction of new tests, or whether the overall market environment still influences their stock price.
Market capitalization of the company, segment and market as a whole
TLIS - Market capitalization of the company Talis Biomedical
Talis Biomedical's market capitalization tells the story of a company attempting to create a fast and accurate diagnostic platform for infectious diseases. Its post-SPAC fallout is a narrative of its COVID-19 test failure and subsequent struggle for survival. Its trajectory exemplifies the shattering of hopes in diagnostics.
TLIS - Share of the company's market capitalization Talis Biomedical within the market segment - Diagnostic medical equipment
Talis Biomedical is developing a platform for rapid molecular diagnostics of infectious diseases. Its market capitalization reflects both the technology's potential and the challenges of its commercialization. The chart below shows how the market assesses its competitiveness.
Market capitalization of the market segment - Diagnostic medical equipment
Talis Biomedical is a company that has developed a system for rapid molecular diagnostics of infectious diseases. The chart below shows the market capitalization of this sector. Its dynamics reflect both the enormous need for rapid diagnostics and the intense competition and challenges associated with commercializing new platforms.
Market capitalization of all companies included in a broad market index - GURU.Markets
Talis Biomedical is a molecular diagnostics company. Its market capitalization reflects the importance of fast and accurate tests for modern medicine. Its performance on the overall chart tells the story of how the diagnostics industry is finding its new path after its pandemic boom.
Book value capitalization of the company, segment and market as a whole
TLIS - Book value capitalization of the company Talis Biomedical
Talis Biomedical's book value represents the capital it invested in developing a rapid molecular diagnostic platform. This book value reflects the underlying assets of this technology company, which has faced significant challenges. How has this asset changed since the COVID-19 test failure? The chart below tells its story.
TLIS - Share of the company's book capitalization Talis Biomedical within the market segment - Diagnostic medical equipment
Talis Biomedical is developing a platform for rapid molecular diagnostics of infectious diseases. The chart shows the proportion of its R&D and manufacturing assets, reflecting the physical foundation on which its diagnostic tests are built.
Market segment balance sheet capitalization - Diagnostic medical equipment
Talis, a molecular diagnostics company, has a moderately capital-intensive business. It requires R&D and manufacturing capabilities for its tests. The BCap_Seg chart for the medical equipment sector shows that innovation requires a material base.
Book value of all companies included in the broad market index - GURU.Markets
Talis' assets include its technology and compact diagnostic platform for rapid molecular testing of infectious diseases. Its balance sheet reflects its patents and manufacturing capabilities. The chart shows the player's net worth in the point-of-care diagnostics market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Talis Biomedical
Talis Biomedical has developed a system for rapid molecular diagnostics of infectious diseases. Its strength lies in its technology and equipment. Its market capitalization reflects its belief that rapid and accurate point-of-care diagnostics will be the future of medicine, despite facing intense competition.
Market to book capitalization ratio in a market segment - Diagnostic medical equipment
Talis Biomedical has developed a rapid molecular diagnostic platform. Its very low valuation, often below its cash flow, reflects the significant challenges of commercializing the product and the highly competitive diagnostics market post-pandemic.
Market to book capitalization ratio for the market as a whole
Talis Biomedical is developing a rapid molecular diagnostics platform. Its value is determined by its technology and its potential in the testing market. This chart shows the premium investors are willing to pay for innovations in medical diagnostics, especially in light of the increased demand for rapid tests.
Debts of the company, segment and market as a whole
TLIS - Company debts Talis Biomedical
Talis Biomedical, a company that developed a rapid molecular diagnostic system for infectious diseases, is using capital to commercialize its platform. This chart shows how the company is funding its efforts to enter the competitive point-of-care diagnostics market, which requires significant investment.
Market segment debts - Diagnostic medical equipment
Talis Biomedical developed a rapid molecular diagnostic platform. However, the company faced challenges in commercializing it. This chart reflects its challenging financial situation and shows how it is managing its resources in an effort to bring its product to market or find a new strategic direction.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Talis Biomedical
Talis Biomedical has developed a system for rapid molecular diagnostics of infectious diseases. This chart shows the company's reliance on debt to complete development, obtain approvals, and commercialize its diagnostic platform. It is an indicator of its financial risk in the competitive landscape.
Market segment debt to market segment book capitalization - Diagnostic medical equipment
Talis Biomedical developed a compact molecular diagnostic platform for rapid testing of infectious diseases. The company encountered difficulties bringing the product to market. The chart shows debt trends in the sector, illustrating how capital-intensive and complex the commercialization of new medical devices is.
Debt to book value of all companies in the market
Talis Biomedical is developing a platform for rapid molecular diagnostics of infectious diseases, which requires investment in R&D and manufacturing. This chart, showing the overall market debt burden, helps assess how the diagnostics company is funding its innovations and the sustainability of its debt strategy on the path to commercialization.
P/E of the company, segment and market as a whole
P/E - Talis Biomedical
Talis Biomedical has developed a rapid molecular diagnostic platform for point-of-care use. This chart shows how the market is evaluating its technology. The dynamics reflect its struggle to commercialize the platform and competition in the diagnostic testing market.
P/E of the market segment - Diagnostic medical equipment
This chart illustrates the average P/E for the medical diagnostics sector. It serves as a backdrop for Talis Biomedical, with its molecular testing platform. It shows how more successful companies are valued, providing context for the valuation of Talis, which has faced challenges in commercializing its product.
P/E of the market as a whole
Talis Biomedical is a molecular diagnostics company that faced significant challenges in bringing its product to market. Its valuation reflects not general market trends, but rather its struggle to survive and its ability to address these challenges and prove the value of its technology in a competitive environment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Talis Biomedical
This chart from Talis Biomedical Corporation, a company that developed a molecular diagnostic platform, shows market expectations for the future adoption of its system. It reflects forecasts for demand for rapid and accurate point-of-care infectious disease tests.
%20P%2FE%20Talis%20Biomedical&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Talis-Biomedical&v=1772613813230 "Chart of the company's future (projected) P/E Talis Biomedical")
Future (projected) P/E of the market segment - Diagnostic medical equipment
Talis Biomedical has developed a rapid molecular diagnostic platform, Talis One, for point-of-care testing for infectious diseases like COVID-19. The chart shows forecasts for the medical diagnostics sector. This helps assess the market's view of Talis's prospects after the pandemic and its ability to compete with other rapid testing systems.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Diagnostic-medical-equipment&v=1772613813270 "Future (projected) P/E graph of the market segment - Diagnostic medical equipment")
Future (projected) P/E of the market as a whole
Talis Biomedical Corporation develops molecular diagnostic tests for point-of-care use. The company aims to accelerate the diagnosis of infectious diseases. This overall market sentiment graph influences the valuation of diagnostic companies, especially after the decline in interest in the sector following the pandemic.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772613813391 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Talis Biomedical
Talis Biomedical developed a rapid molecular diagnostic platform. The company encountered difficulties bringing its product to market. This timeline reflects the challenges associated with commercializing complex medical devices, even during the pandemic, when demand for tests was high.
Profit of companies in the market segment - Diagnostic medical equipment
Talis Biomedical has developed a system for rapid molecular diagnostics of infectious diseases at the point of care. This graph, reflecting the sector's profitability, demonstrates the importance of rapid diagnostics. Their Talis One platform is designed to deliver accurate results in minutes, which could revolutionize the diagnosis of diseases like COVID-19 and influenza.
Overall market profit
Talis Biomedical has developed a rapid molecular diagnostic platform for point-of-care use, such as in a doctor's office. The company's success depends on the commercialization of this platform. Demand for rapid diagnostics is high, and the overall economic stability shown in the graph facilitates the implementation of such advanced technologies in medical practice.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Talis Biomedical
Talis Biomedical has developed a compact molecular diagnostic platform for rapid point-of-care testing of infectious diseases. This timeline reflects analysts' expectations for the platform's commercialization and its adoption in clinics and physician offices, which is dependent on regulatory approvals and competition.
%20profit%20of%20the%20company%20Talis%20Biomedical&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Talis-Biomedical&v=1772613813677 "Graph of future (projected) profit of the company Talis Biomedical")
Future (predicted) profit of companies in the market segment - Diagnostic medical equipment
Talis Biomedical has developed a system for rapid molecular testing for infectious diseases at the point of care. The company has encountered challenges in commercializing its product. Assessing its prospects depends on its ability to overcome these challenges. This chart for the medical diagnostics sector provides only a general overview; the key factors are the company's internal successes.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Diagnostic-medical-equipment&v=1772613813757 "Graph of future (predicted) profits of companies in a market segment - Diagnostic medical equipment")
Future (predicted) profit of the market as a whole
Talis Biomedical is developing a platform for rapid molecular diagnostics. Demand for such systems depends on the needs of the healthcare system. The overall profit forecast shown in the graph influences the budgets of clinics and laboratories and their willingness to invest in new diagnostic technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772613813888 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Talis Biomedical
Talis Biomedical has developed a rapid molecular diagnostic platform for infectious disease testing. The chart shows how the market estimates its revenue from sales of systems and tests. It reflects the demand for point-of-care testing and the challenges associated with commercialization in a competitive environment.
P/S market segment - Diagnostic medical equipment
Talis Biomedical has developed a system for rapid molecular diagnostics of infectious diseases directly at the point of care. The company's revenue will depend on the commercialization of its platform. This chart reflects the average valuation in the sector, helping to understand how investors view the potential of Talis' technology for decentralized diagnostics.
P/S of the market as a whole
Talis Biomedical is a company that has developed a compact molecular diagnostic platform for rapid point-of-care testing for infectious diseases. This chart, showing the average market revenue estimate, helps understand how investors value this company, which aims to decentralize diagnostics and make it more accessible.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Talis Biomedical
Talis Biomedical is a molecular diagnostics company that developed the Talis One platform for rapid, point-of-care testing for infectious diseases. This chart reflects investor expectations regarding future demand for decentralized diagnostics and the company's ability to commercialize its platform.
%20P%2FS%20Talis%20Biomedical&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Talis-Biomedical&v=1772613814126 "The graph of the company's future (projected) P/S Talis Biomedical")
Future (projected) P/S of the market segment - Diagnostic medical equipment
Talis Biomedical Corporation is developing a point-of-care molecular diagnostics platform designed for rapid and accurate testing for infectious diseases. This chart shows the average estimated future sales in the medical diagnostics sector. It helps understand how the market views Talis Biomedical's potential.
%20P%2FS%20market%20segment%20graph%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Diagnostic-medical-equipment&v=1772613814214 "Future (projected) P/S market segment graph - Diagnostic medical equipment")
Future (projected) P/S of the market as a whole
Talis Biomedical has developed a rapid molecular diagnostic platform for detecting infectious diseases at the point of care. This chart reflects overall investor sentiment. The company's technology aims to accelerate diagnostics, which is critical for combating the spread of infections and promptly initiating treatment.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772613814280 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Talis Biomedical
This chart shows sales of Talis Biomedical, a molecular diagnostics company. It has developed a platform for rapid testing for infectious diseases. Revenue is generated from sales of these systems and test cartridges. The trend reflects the demand for point-of-care diagnostics.
Sales of companies in the market segment - Diagnostic medical equipment
Talis Biomedical Corporation is developing a molecular diagnostic platform for rapid point-of-care testing for infectious diseases. This graph reflects the growth of the diagnostics market. The company's goal is to make accurate testing as fast and accessible as rapid tests, which could revolutionize the fight against infections.
Overall market sales
Talis Biomedical is developing a platform for rapid molecular diagnostics of infectious diseases. Its commercial success depends on the implementation of this system in healthcare facilities. The overall economic situation, shown in this chart, influences hospital budgets for the purchase of new diagnostic equipment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Talis Biomedical
Talis Biomedical has developed a compact molecular diagnostic platform for rapid point-of-care testing of infectious diseases. Future revenues are dependent on its commercial launch. The chart shows the forecast for the competitive rapid diagnostics market.
%20sales%20of%20the%20company%20Talis%20Biomedical&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Talis-Biomedical&v=1772613814641 "Schedule of future (projected) sales of the company Talis Biomedical")
Future (projected) sales of companies in the market segment - Diagnostic medical equipment
Talis Biomedical has developed a compact molecular diagnostic platform designed for rapid testing for infectious diseases at the point of care, such as doctors' offices and clinics. This chart shows the forecast for the entire diagnostic equipment market, where decentralized testing is a key trend.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Diagnostic-medical-equipment&v=1772613814741 "Schedule of future (projected) sales of companies in the market segment - Diagnostic medical equipment")
Future (projected) sales of the market as a whole
Talis Biomedical has developed a rapid molecular diagnostic platform for point-of-care use. The company's success hinges on the commercial launch and adoption of its system. This timeline, reflecting overall healthcare spending, influences the willingness of clinics and hospitals to invest in new diagnostic platforms.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772613814757 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Talis Biomedical
Talis Biomedical has developed a rapid molecular diagnostic platform. The company's profitability depends on the successful launch of this system and its cartridges, particularly for infectious disease testing. This chart illustrates the enormous development and commercialization costs, as well as the challenges faced by new players in the point-of-care diagnostics market.
Market segment marginality - Diagnostic medical equipment
Talis Biomedical has developed a rapid molecular diagnostic platform for point-of-care testing of infectious diseases. Profitability depends on the commercial success and widespread adoption of their system. This graph reflects the operational and financial challenges the company faced in bringing its complex technology to market.
Market marginality as a whole
Talis Biomedical is a company that has developed a compact molecular diagnostic platform for rapid testing for infectious diseases, including COVID-19, at the point of care (e.g., in a doctor's office). This overall profitability curve isn't as important to them. Their success depends on the accuracy of their system and their ability to compete in a crowded diagnostics market.
Employees in the company, segment and market as a whole
Number of employees in the company Talis Biomedical
Talis Biomedical has developed a rapid, point-of-care molecular diagnostic system. Its team consists of engineers and scientists. This graph charts its journey from development and regulatory approvals to commercialization efforts for its diagnostic platform.
Share of the company's employees Talis Biomedical within the market segment - Diagnostic medical equipment
Talis Biomedical has developed a platform for point-of-care molecular diagnostics. This chart reflects its strength in the medical device niche. It shows the size of the team of engineers and clinicians working to commercialize this technology, aiming to make rapid and accurate infectious disease diagnostics accessible beyond centralized laboratories.
Number of employees in the market segment - Diagnostic medical equipment
Talis Biomedical Corporation is developing a point-of-care molecular diagnostics platform. This chart illustrates employment trends in the diagnostics sector. Fluctuations in hiring of engineers and scientists reflect the challenges and intense competition in creating fast, accurate, and affordable diagnostic systems for use outside of laboratories.
Number of employees in the market as a whole
Talis Biomedical has developed a system for rapid molecular diagnostics of infectious diseases. The implementation of its platform depends on the budgets of medical institutions. The overall economic stability reflected in this graph allows hospitals and laboratories to invest in new technologies that can speed up diagnostics and improve patient care.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Talis Biomedical (TLIS)
Talis Biomedical developed a platform for rapid molecular diagnostics (including COVID-19) at the point of care. This business requires R&D (platform) and manufacturing (cartridges). The chart shows how the market valued their technology. The high cost per employee during the pandemic reflected hopes for their platform, while the subsequent decline reflected a loss of faith in its commercial potential.
%20of%20the%20company%20Talis%20Biomedical%20(TLIS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Talis-Biomedical-TLIS&v=1772613815194 "Chart of market capitalization per employee (in thousands of dollars) of the company Talis Biomedical (TLIS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
Talis Biomedical has developed a system for rapid molecular diagnostics of infectious diseases. The company's value is based on the potential of its diagnostic platform. This chart shows how investors evaluate its technology and its ability to compete in the large and important diagnostics market.
%20by%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Diagnostic-medical-equipment&v=1772613815341 "Market capitalization per employee (in thousands of dollars) by market segment - Diagnostic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
Talis Biomedical developed a platform for rapid molecular diagnostics of infectious diseases. The chart reflects the valuation of a company in the diagnostics sector facing challenges. It illustrates how the market overestimates the value of a technology when the path to commercialization proves more challenging than expected.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772613815382 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Talis Biomedical (TLIS)
Talis Biomedical developed a rapid, point-of-care molecular diagnostic platform. The idea was to quickly test for COVID-19 and other infections. However, the company faced challenges. This chart illustrates the struggle to commercialize: huge R&D and manufacturing costs per employee, coupled with very low sales.
%20Chart%20Talis%20Biomedical%20(TLIS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Talis-Biomedical-TLIS&v=1772613815395 "Company Profit Per Employee (in thousands of dollars) Chart Talis Biomedical (TLIS)")
Profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment
Talis Biomedical is a company that developed a rapid molecular diagnostic system (PCR tests) for point-of-care use. The company encountered difficulties commercializing its platform. This metric reflects the balance between R&D costs and the complexity of bringing a new diagnostic device to market.
%20in%20the%20market%20segment%20-%20Diagnostic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Diagnostic-medical-equipment&v=1772613815447 "Chart of profit per employee (in thousands of dollars) in the market segment - Diagnostic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
Talis Biomedical (TLIS) is a biotech company that developed a platform (Talis One) for rapid molecular diagnostics (similar to COVID tests). It is an R&D company. This graph likely shows losses per employee, reflecting the failure to commercialize their platform after the pandemic.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772613815467 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Talis Biomedical (TLIS)
Talis Biomedical has developed a compact molecular diagnostic platform for rapid testing of infectious diseases. This graph reflects the commercial potential of its system. Increased revenue per employee will reflect successful deployment of its devices in clinics and hospitals, as well as sales of test cartridges.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Talis-Biomedical-TLIS&v=1772613815501 "Sales chart per company employee Talis Biomedical (TLIS)")
Sales per employee in the market segment - Diagnostic medical equipment
Talis Biomedical (TLIS) developed the Talis One platform for rapid molecular diagnostics (PCR) at the point of care. This graph shows the revenue (from sales of devices and cartridges) generated by each employee (engineer, salesperson). This measures their commercial progress in the competitive diagnostics segment.
Sales per employee for the market as a whole
Talis Biomedical (TLIS) is developing a platform (Talis One) for rapid molecular diagnostics (COVID and flu tests) at the point of care (e.g., in a doctor's office). The company is in the commercialization phase. This chart shows how successfully the company is beginning to generate revenue from sales of its devices and cartridges.
Short shares by company, segment and market as a whole
Shares shorted by company Talis Biomedical (TLIS)
Talis Biomedical developed a "lab-in-a-box" diagnostic platform, initially focused on COVID-19 testing. The bearish sentiment shown by this chart is a bet that demand for COVID-19 tests has disappeared and that its platform is uncompetitive for other diagnostics.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Talis-Biomedical-TLIS&v=1772613815666 "Short Shares Chart for the Company Talis Biomedical (TLIS)")
Shares shorted by market segment - Diagnostic medical equipment
Talis Biomedical (TLIS) has developed a platform for rapid, direct-to-patient molecular diagnostics of infectious diseases. Since the pandemic, this market has become extremely competitive. This chart demonstrates the collective pessimism of investors regarding the entire medical diagnostics sector. High values indicate the market's lack of confidence in the commercial success of new diagnostic platforms.
Shares shorted by the overall market
Talis Biomedical is a diagnostics company trying to bring its tests to market. This chart measures overall fear. When investors are pessimistic, they are skeptical of small medtech companies. They see TLIS as a cash burner trying to compete with giants and are selling off its shares, fearing the company won't survive the crisis.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Talis Biomedical (TLIS)
Talis Biomedical (TLIS) developed the Talis One platform for rapid molecular diagnostics (PCR) at the point of care, including for COVID-19. The company has encountered problems. This indicator measures the strength of speculative movements. It shows when short bursts of hope (above 70) or deep disappointment (below 30) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Talis-Biomedical-TLIS&v=1772613815767 "RSI 14 indicator chart for the company's stock Talis Biomedical (TLIS)")
RSI 14 Market Segment - Diagnostic medical equipment
Talis Biomedical is a "PCR test at home" (or at the doctor's office). They (like Cue Health) are developing a *fast*, *cheap* "molecular" *diagnostic* platform (Talis One). The "Diagnostic medical equipment" sector (medtech/diagnostics) thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is TLIS's decline just their "niche" or a *general* decline?
RSI 14 for the overall market
Talis Biomedical (TLIS) is a cash-burning biotech. This chart is its lifeline. During periods of market euphoria, investors are willing to "buy the dream" and fund unprofitable R&D projects. During moments of panic, the cash tap is turned off, and investors demand profits rather than promises, putting TLIS at risk of survival.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TLIS (Talis Biomedical)
Talis Biomedical is developing a compact diagnostic platform (Talis One) for point-of-care molecular testing (e.g., in a doctor's office). This chart shows the analysts' average 12-month forecast, reflecting their view on the company's ability to commercialize this platform after the pandemic.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TLIS-Talis-Biomedical&v=1772613815883 "A chart showing analyst consensus forecasts for the expected stock price. TLIS (Talis Biomedical)")
The difference between the consensus estimate and the actual stock price TLIS (Talis Biomedical)
Talis (TLIS) is a "laboratory in a box." It's a medical technology company that developed a platform (Talis One) for rapid molecular diagnostics (COVID, flu) at the patient's bedside. This chart measures the gap between the current price and the consensus target price. It shows whether experts believe the company will rebound and its assets will be valuable.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TLIS-Talis-Biomedical&v=1772613815920 "A chart showing the difference between the consensus forecast and the actual stock price. TLIS (Talis Biomedical)")
Analyst consensus forecast for stock prices by market segment - Diagnostic medical equipment
Talis Biomedical is a company that attempted to enter the market for rapid molecular diagnostics (COVID and flu tests) at the point of care, but encountered setbacks. This chart shows general expectations for the diagnostic equipment sector. It reflects whether experts believe the COVID testing market is overheated.
Analysts' consensus forecast for the overall market share price
Talis Biomedical (TLIS) is a "bedside laboratory." They developed a rapid molecular test (Talis One) designed to quickly diagnose COVID, flu, and other infections. This chart shows the overall risk appetite. It reflects how willing investors are to invest in post-COVID diagnostics startups seeking their niche.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Talis Biomedical
Talis Biomedical is developing a compact diagnostic platform (Talis One) for point-of-care molecular testing, including tests for infectious diseases. This is a highly competitive market. This chart is an integrated assessment weighing technological risks, the difficulty of obtaining FDA approval, and the company's ability to commercialize its platform in a highly competitive environment.
AKIMA Market Segment Index - Diagnostic medical equipment
Talis Biomedical (TLIS) is a medical diagnostic equipment company. They are developing a compact system (Talis One) that aims to provide molecular diagnostics (similar to PCR) in 30 minutes at the doctor's office. This chart compares their composite index to the industry average.
The AKIM Index for the overall market
Talis Biomedical is a diagnostics company developing molecular point-of-care tests. It is currently winding down its operations. This chart, reflecting the market average, is a backdrop. It helps assess how the distressed diagnostics asset compares to overall macroeconomic trends.
